Home » News

The Myeloma Beacon To Report The Latest Research From The Upcoming American Society Of Hematology Annual Meeting (ASH 2012)

5 Comments By
Published: Nov 30, 2012 3:39 pm

The American Society of Hematology (ASH) will kick off its 54th annual meeting next Saturday, December 8. This year’s meeting will run through Tuesday, December 11 and will be held in Atlanta.

Similar to past years, over 20,000 people are expected to attend the meeting to listen to experts from around the world discuss current research regarding the biology, diagnosis, treatment, and progression of various blood diseases, including multiple myeloma.

The ASH meeting, along with the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) meetings, are the three key annual scientific meetings where important new myeloma-related research findings are reported.

Among these three meetings, ASH is generally viewed as the most important for myeloma researchers, patients, and caregivers.  This is due both to the volume and the importance of the research usually presented at the meeting.

At this year’s ASH meeting, almost 200 oral presentations and more than 500 poster presentations will summarize research focused on myeloma.

As in previous years, The Beacon will provide in-depth coverage of the ASH meeting.  A team of editors and writers, some of whom will be on site in Atlanta, will be publishing daily summaries and in-depth research reviews during and after the meeting.

Each day of the meeting, The Beacon will publish one or more daily updates summarizing the key events and findings of the day.

During the meeting and for several weeks thereafter, The Beacon will also publish individual news articles looking in depth at important findings presented at the ASH meeting.

Most of the research findings presented at scientific meetings are communicated in either oral presentations or poster summaries.

Research findings presented in oral presentations are generally considered particularly important, either because the subject itself is important, or the results are based on substantial amounts of evidence (for example, a sizable clinical trial).

Other research findings are presented during poster sessions, in which researchers display summaries of their results on posters in a large exhibition hall.

Compared to the research summarized during oral presentations, the findings in poster summaries generally are in earlier stages of development.  They may involve laboratory research, clinical trials with just a small number of patients, or early results from ongoing clinical trials.

Presentations related to myeloma will kick off early on the first day of the ASH meeting with an educational program called “Keeping Pace With Advances In Multiple Myeloma.” The session will include talks given by Dr. Gareth Morgan of Royal Marsden Hospital in the United Kingdom; Dr. Vincent Rajkumar of the Mayo Clinic; and Dr. Antonio Palumbo from the University of Torino in Italy.

For the most part, though, the myeloma-related research presented on Saturday will be in the form of poster summaries made available during poster sessions in the evening.

Both Sunday and Monday, however, will be packed with oral and poster presentations related to myeloma.

Oral presentations about potential new myeloma treatments — including trial results for ARRY-520, BHQ880, circularly permuted TRAIL, daratumumab, dinaciclib, elotuzumab, lorvotuzumab mertansine, MLN9708 (ixazomib), oprozomib, pomalidomide, tabalumab, and Zolinza (vorinostat) — will be spread across Sunday and Monday.  An oral presentation of results from a study of Treanda (bendamustine) will also be presented on Tuesday.

Some of these studies are testing the new drugs as monotherapy and others are testing them in combination with currently-approved myeloma treatments.

There will also be a number of studies further evaluating the efficacy and safety of Kyprolis (carfilzomib), which was approved to treat myeloma earlier this year.

In addition to all of the oral presentations on Sunday and Monday, poster sessions with long lists of myeloma-related research results are scheduled for both of those evenings.

The myeloma-related sessions will conclude Tuesday morning.  Several myeloma-related oral sessions are scheduled simultaneously for first thing in the morning.

Of particular note, one of Tuesday’s presentations will be about the complete results from the Phase 3 study showing that pomalidomide plus dexamethasone (Decadron) significantly extends overall survival as compared to high-dose dexamethasone alone.  Results from other pomalidomide studies will be presented earlier during the meeting.

Additional information about the ASH meeting, including details about registration, the meeting schedule, and presentation and poster abstracts, can be found at the ASH meeting website.

Beacon coverage of myeloma-related research presented at recent scientific meetings can be found at these links: ASCO 2012 Meeting and EHA 2012 Meeting.

Tags: , ,


Related Articles:

5 Comments »

  • suzierose said:

    Myeloma Beacon Staff,

    I know you have lots to cover…but will you please make certain to cover this presentation?

    There will be an outstanding presentation on Mon of ASH by Dr Neha Korde…will you please cover and provide details?

    Thanks

  • Terry L said:

    I agree with Suzierose. She is Dr. Landgren’s colleague at the NIH and a fantastic doctor as both a researcher and attending physician. She will present on the NIH’s CRD–carfilzomib/rev/dex trial for newly diagnosed which is run by Dr. Landgren. He will also be at ASH and is an amazing physician dedicated to eradicating MM. I, and several other MB posters, are current participants in this trial. My results have been personally great with few side effects. Currently, this is the only open CRD trial in the world for newly diagnosed. The Michigan CRD trial of Dr. Jakubowiak which has been widely reported on is closed. Hopefully, this protocol can become available to others soon as an option as it has seems to work well with few toxicities. Terry L. from NJ

  • nancy shamanna said:

    Hi , That is an interesting link into the ASH conference…20,000 participants ..wow! And I gather that it is mostly related to blood cancers. i see several papers or posters with Dr. Nazhir Bahlis and also Dr. Paolo Neri as authors along with others., They are from Calgary, and are presenting topics related to myeloma! So I will be following all of your reports with interest.

  • Beacon Staff said:

    Suzierose and Terry L, Dr. Korde’s talk about CRd is on our list of talks to attend and cover. Stay tuned.

  • tim said:

    i am interested in learning more about dr palumbo’s discussion; “have drug combinations supplanted stem cell transplantation in myeloma?” can anyone assist? has a summary been created for discussion?

    thank you!